Company: RNAC
Filing Date: 2025-01-08
Form Type: 424B3
Source: 0001140361-25-000626
Chunk: 1

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-01-08
Form: 424B3
Chunk 1
---
ORPORATED BY REFERENCE IN THIS PROSPECTUS CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.**

#### Leerink Partners

#### The date of this prospectus is January 8, 2025.
TABLE OF CONTENTS

TABLE OF CONTENTS

| ABOUT THIS PROSPECTUS                                |     |  1 |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS |     |  2 |
| WHERE YOU CAN FIND MORE INFORMATION                  |     |  4 |
| INCORPORATION BY REFERENCE                           |     |  5 |
| PROSPECTUS SUMMARY                                   |     |  6 |
| RISK FACTORS                                         |     |  9 |
| USE OF PROCEEDS                                      |     | 10 |
| DESCRIPTION OF COMMON STOCK                          |     | 11 |
| DIVIDEND POLICY                                      |     | 15 |
| DILUTION                                             |     | 16 |
| PLAN OF DISTRIBUTION                                 |     | 18 |
| LEGAL MATTERS                                        |     | 19 |
| EXPERTS                                              |     | 20 |

i

#### TABLE OF CONTENTS

### ABOUT THIS PROSPECTUS
**This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission, or the SEC, utilizing a “shelf” registration process, and relates to the offering of our Common Stock. Under this shelf registration process, we may offer and sell shares of our Common Stock having an aggregate offering price of up to $100,000,000 from time to time under this prospectus at prices and on terms to be determined by market conditions at the time of the offering. Before buying any of the Common Stock that we are offering, we urge you to carefully read this prospectus and all of the information incorporated by reference herein, as well as the additional information described under the heading “ Where You Can Find More Information .” These documents contain important information that you should consider when making your investment decision.

When we refer to “Cartesian,” “we,” “our,” “us,” the “Company” and “our company” in this prospectus, we mean Cartesian Therapeutics, Inc., unless otherwise specified. When we refer to “you